Luminex (NASDAQ: LMNX) is one of 79 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its competitors? We will compare Luminex to similar companies based on the strength of its earnings, profitability, risk, institutional ownership, analyst recommendations, valuation and dividends.

Valuation and Earnings

This table compares Luminex and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Luminex $270.64 million $13.81 million 32.17
Luminex Competitors $2.18 billion $239.60 million -30.19

Luminex’s competitors have higher revenue and earnings than Luminex. Luminex is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Luminex and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Luminex 9.52% 6.01% 5.47%
Luminex Competitors -315.50% -23.22% -9.55%

Analyst Recommendations

This is a breakdown of recent recommendations for Luminex and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Luminex 1 3 0 0 1.75
Luminex Competitors 272 1885 3383 106 2.59

Luminex currently has a consensus price target of $19.33, indicating a potential downside of 8.93%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 9.56%. Given Luminex’s higher possible upside, research analysts clearly believe Luminex is more favorable than its competitors.

Institutional & Insider Ownership

79.3% of Luminex shares are held by institutional investors. Comparatively, 51.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 6.9% of Luminex shares are held by insiders. Comparatively, 18.2% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Luminex has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Luminex’s competitors have a beta of 1.24, suggesting that their average share price is 24% more volatile than the S&P 500.

Dividends

Luminex pays an annual dividend of $0.24 per share and has a dividend yield of 1.1%. Luminex pays out 36.4% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.9% and pay out 26.2% of their earnings in the form of a dividend.

Summary

Luminex competitors beat Luminex on 8 of the 15 factors compared.

Luminex Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

Receive News & Ratings for Luminex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Co. and related companies with MarketBeat.com's FREE daily email newsletter.